We believe Bio-Rad has been able to maintain a top-three market position through niche specialization and by offering one-stop shopping for blood bank and transfusion customers.

Bio-Rad offers a wide variety of platforms, reagents, data management, and connectivity solutions to address different volume blood typing needs. Using Bio-Rad's IH-Com patient data management ...

Following last week's earnings report, Bio-Rad Laboratories' six analysts are forecasting 2025 revenues to be US$2.60b, approximately in line with the last 12 months. Statutory earnings per share ...

Bio-Rad operates with decent financial strength. The firm’s main debt obligation is a $425 million balance of senior notes that are coming due in December 2020, and Bio-Rad also entered into an ...

Revenue Growth: Bio-Rad Laboratories's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -6.26%.

Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.6 billion in revenues in 2024.

Bio-Rad Receives U.S. FDA Clearance for the IH-Reader 24, Expanding the Company’s Offering for the Blood Typing Market October 29, 2018 08:30 AM Eastern Daylight Time ...